Table 1.
Patient, disease, and transplant characteristics
| Type of transplant | ||||
|---|---|---|---|---|
| Variable | Auto-HSCT | 10/10 UD-HSCT | 9/10 UD-HSCT | p |
| Number (total: 2879) | 1202 | 1302 | 375 | |
| Gender, n (%) | 0.046 | |||
| Male | 681 (57) | 694 (53) | 188 (50) | |
| Female | 518 (43) | 608 (47) | 187 (50) | |
| WBC at diagnosis (×109/l), median (range) | 13.8 (0.3–820) | 10 (0.3–900) | 9.9 (0.2–790) | 0.32 |
| Missing | 592 | 308 | 99 | |
| Cytogenetic risk, n (%) | <10−4 | |||
| Good | 392 (33) | 137 (11) | 26 (7) | |
| Intermediate | 624 (51) | 550 (42) | 165 (44) | |
| Poor | 186 (16) | 615 (47) | 184 (49) | |
| Molecular aberrations, n (%) | ||||
| NPM1 mutation | 0.001 | |||
| Absent | 64 (34) | 150 (49) | 41 (53) | |
| Present | 124 (66) | 154 (51) | 37 (47) | |
| Missing | 438 | 280 | 96 | |
| FLT3-ITD | <10−4 | |||
| Absent | 159 (70) | 178 (48) | 48 (44) | |
| Present | 68 (30) | 197 (52) | 61 (56) | |
| Missing | 399 | 209 | 66 | |
| CEBPA mutation | 0.07 | |||
| Absent | 40 (82) | 109 (90) | 33 (97) | |
| Present | 9 (18) | 12 (10) | 1 (3) | |
| Missing | 577 | 463 | 140 | |
| No. of induction courses to reach CR1, n (%) | <10−4 | |||
| 1 | 617 (51) | 722 (56) | 187 (50) | |
| More than 1 | 195 (17) | 408 (31) | 122 (33) | |
| Missing | 390 (32) | 172 (13) | 66 (17) | |
| MRD status at transplant | 0.53 | |||
| MRD negative | 361 (79) | 352 (73) | 81 (76) | |
| MRD positive | 99 (21) | 132 (27) | 26 (24) | |
| Missing | 742 | 818 | 268 | |
| Median age at transplant, years (range) | 49 (18–78) | 51 (18–76) | 49 (18–69) | 0.004 |
| Median interval diagnosis transplant, days (range) | 158 (75–813) | 174 (66–997) | 177 (83–766) | <10−4 |
| Median interval CR1 transplant, days (range) | 109 (21–365) | 115 (18–447) | 121 (21–348) | 0.41 |
| Missing | 390 | 172 | 66 | |
| Median year of transplant (range) | 2008 (05–13) | 2010 (05–13) | 2010 (05–13) | <10−4 |
| Stem cell source, n (%) | <10−4 | |||
| BM | 53 (4) | 258 (20) | 58 (16) | |
| PBSCs | 1149 (96) | 1044 (80) | 317 (84) | |
| TBI-including conditioning, n (%) | <10−4 | |||
| No | 1112 (93) | 936 (72) | 262 (70) | |
| Yes | 85 (7) | 364 (28) | 113 (30) | |
| Conditioning intensity, n (%) | ||||
| MAC | – | 619 (48) | 194 (52) | |
| RIC | – | 677 (52) | 180 (48) | |
| Median follow-up, months (range) | 45 (1–128) | 36 (1–119) | 25 (1–113) | |
Legend: BM bone marrow, CEBPA CCAAT/enhancer-binding protein alpha, CR1 first complete remission, FLT3-ITD fms-like tyrosine kinase-internal tandem duplication, MAC myeloablative, MRD minimal residual disease, NPM1 nucleophosmin, PBSCs peripheral blood stem cells, RIC reduced-intensity, TBI total-body irradiation, WBC white blood cells